Evidence map›Paper›PMID 29557075›Full record

ArticlePharmaceutical research2018

Simulation of Stimuli-Responsive and Stoichiometrically Controlled Release Rate of Doxorubicin from Liposomes in Tumor Interstitial Fluid.

Eiichi Yamamoto, Kenji Hyodo, Takuya Suzuki, Hiroshi Ishihara, Hiroshi Kikuchi, Masaru Kato

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Eiichi YamamotoFormulation Research, Pharmaceutical Science & Technology Core Function Unit, Eisai Product Creation Systems, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan. e-yamamoto@hhc.eisai.co.jp.ORCID http://orcid.org/0000-0003-2043-8790
Kenji HyodoFormulation Research, Pharmaceutical Science & Technology Core Function Unit, Eisai Product Creation Systems, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan.
Takuya SuzukiFormulation Research, Pharmaceutical Science & Technology Core Function Unit, Eisai Product Creation Systems, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan.
Hiroshi IshiharaFormulation Research, Pharmaceutical Science & Technology Core Function Unit, Eisai Product Creation Systems, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan.
Hiroshi KikuchiTsukuba Research Laboratories, Eisai Co. Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki, 300-2635, Japan.
Masaru KatoGraduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan.
Eisai (Japan) · JPShowa University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo simulate the stimuli-responsive and stoichiometrically controlled doxorubicin (DOX) release from liposomes in in vivo tumor interstitial fluid (TIF), the effect of ammonia concentration and pH on the DOX release from liposomes in human plasma at 37°C was quantitatively evaluated in vitro and the release rate was calculated as a function of ammonia concentration and pH.

methodsHuman plasma samples spiked with DOX-loaded PEGylated liposomes (PLD) or Doxil

resultsAccelerated DOX release (%) from liposomes was observed as the increase of ammonia concentration and pH of the matrix, and the decrease of encapsulated DOX concentration. The release rate was expressed as a function of the ammonia concentration and pH by using Henderson-Hasselbalch equation.

conclusionsThe DOX release from PLD in TIF was expressed as a function ammonia concentration and pH at various DOX concentrations. Further, it was found that the DOX release from liposomes in a simulated TIF was more than 15 times higher than in normal plasma.

Indexed as

Models, BiologicalAmmoniaAntibiotics, AntineoplasticDelayed-Action PreparationsDoxorubicinDrug LiberationExtracellular FluidHydrogen-Ion ConcentrationLiposomesNeoplasmsPolyethylene GlycolsAmmoniaAntibiotics, AntineoplasticDelayed-Action PreparationsDoxorubicinliposomal doxorubicinLiposomesPolyethylene GlycolsDoxil®drug releaseliposomessimulationtumor interstitial fluid

Identifiers

PMID29557075
OpenAlexW2789407180

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.